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INTRODUCTION 
Motoneurons played an essential role in establishing 
the concept that target tissues have an important influ-
ence on the development of innervating neurons. In 
chick embryos, it was demonstrated that the removal of 
leg or wing buds during early developmental stages re-
sulted in a virtually complete loss of the corresponding 
motoneurons analyzed at later developmental stages 
(31). Conversely, the implantation of an additional ex-
tremity anlage resulted in an increase of the number of 
motoneurons projecting into the augmented target area 
(31, 37). The further extension and evaluation of this 
concept, replacing the physiological target of motoneu-
rons by sarcoma tissue, resulted-by a cascade of lucky 
coincidences-in the discovery of nerve growth factor 
(NGF) (summarized in 48), the molecular incarnation 
of the retrograde trophic influence of peripheral target 
cells on sympathetic and subpopulations of sensory 
(both neural crest and placode derived) neurons (sum-
marized in 4, 48, 104). 
In contrast to the importance of motoneurons in es-
tablishing the concept of the trophic influence of target 
tissues on innervating neurons, for a long time very lit-
tle progress was made in identifying molecules responsi-
ble for this trophic support. Experimental achieve-
ments were confined to the demonstration that skeletal 
muscle extract or conditioned medium of primary cul-
tures of skeletal muscle my ob lasts trophically sup-
ported motoneurons in vivo (75) and in vitro (11,21,24, 
25,57, 73, 89, 99). 
This situation has changed dramatically within the 
last few years. Progress was predominantly determined 
by an improvement of the motoneuron cell culture pro-
cedures (3, 10, 12, 33, 34, 39) and the identification of 
neurotrophic molecules in adult and/or embryonic skel-
etal muscles with already known neurotrophic actions 
on other populations of neurons in vitro and in vivo (3, 
13, 34, 36, 38, 39, 45, 54, 58, 80). The importance of 
appropriate culture systems for motoneurons is demon-
strated by the fact that, for a long time, no single, de-
fined molecule could be demonstrated to have a con-
vincing trophic action on motoneurons. Even molecules 
like CNTF, which have been shown later to have a dis-
tinct survival effect in vitro and in vivo on motoneurons, 
were initially reported to have no effect on mixed spinal 
cord cultures of the chick (51). Now we have a large 
number of molecules which show such effects, and it is 
the goal of present and future investigations to eluci-
date their (relative) physiological role during different 
stages of development, their possible pathophysiologi-
cal importance, and, as a consequence, their suitability 
for the treatment of degenerative diseases of motoneu-
rons such as amyotrophic lateral sclerosis (ALS) which, 
so far, are not amenable to any therapy (88, 102). In this 
context, it should be emphasized that, according to 
currently available information, there is not a single hu-
man or animal degenerative disease of the nervous sys-
tem which can causally be linked to an insufficient or 
false (mutated) production of neurotrophic molecule 
(98). However, neurotrophic molecules have been dem-
onstrated to rescue specific neurons from the conse-
quences of a variety of mechanical (axotomy) or chemi-
cal (6-hydroxydopamine, MPTP, excitotoxic amino 
acids) damages (40, 45, 50, 79,93,96, 104, 107). There-
fore, the use of neurotrophic molecules in the treatment 
of degenerative diseases ofthe nervous system is a symp-
tomatic one and strongly encourages further investiga-
tions aimed at a molecular understanding of the patho-
genetic mechanisms of degenerative disorders of the 
nervous system. 
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In the following, we give a brief survey of the mole-
cules with an established action on motoneurons (in vi-
tro and/or in vivo) and the present and potential future 
approaches to the elucidation of the relative physiologi-
cal and pathophysiological importance of these mole-
cules. Finally, we discuss the essential criteria to be con-
sidered for a rational evaluation of neurotrophic mole-
cules in the treatment of degenerative disease of the 
nervous system, in general, and of motoneuron dis-
orders, in particular. 
CILIARY NEUROTROPHIC FACTOR (CNTF) AND 
RELATED MOLECULES 
CNTF was originally identified and partially purified 
as a target-derived neurotrophic factor for parasympa-
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thetic cholinergic neurons of the chick ciliary ganglion 
(1, 32, 69). Further investigations demonstrated that 
CNTF had a much broader spectrum of action in vitro, 
including survival effects on sympathetic, sensory, and, 
more recently, hippocampal, locus coeruleus, and dopa-
minergic mesencephalic neurons (30,41,52,53,94) . 
In the course of investigations aimed at the identifi-
cation and purification of trophic factors for motoneu-
rons in extracts of adult skeletal muscle, a marked moto-
neuron survival activity, eluted from preparative gels, 
had physicochemical properties corresponding to those 
of CNTF isolated from the rat sciatic nerve (Sendtner, 
unpublished observations). The results obtained with 
this enriched preparation could later be confirmed by 
CNTF purified to homogeneity and recombinant CNTF 
(3, 59, 93, 94). 
For embryonic chick motoneurons in culture, CNTF 
has been shown to be the most potent neurotrophic mol-
ecule thus far characterized, displaying half-maximal 
survival at a concentration of 30 pg/ml with a maximal 
survival effect of over 60% of the originally plated moto-
neurons (3). Similar positive effects have also been ob-
served in vivo when CNTF was administered onto the 
chorioallantoic membrane of chick embryos at the same 
developmental stages (70, 77). That CNTF has a direct 
action on motoneurons could be deduced from the fact 
that the survival effect in single motoneuron cultures 
was identical to that in 80% pure low-density cultures 
(94) . The cloning of CNTF was the prerequisite for pro-
ducing large quantities of recombinant CNTF (49, 59, 
100) and for the determination of its developmental ex-
pression and cellular localization (20, 27, 86, 94, 97,100, 
101). These investigations demonstrated that CNTF is 
expressed postnatally in myelinating Schwann cells (27, 
86,97,100,101) and a subpopulation of type I astrocytes 
(20, 101) in the CNS, that CNTF is a cytosolic molecule, 
and that the biological activity, e.g., in the adult sciatic 
nerve, is more than 10,000 _times higher than that of 
(retrogradely) transported NGF in the rat sciatic nerve 
(35, 97, 98). 
The time course of the developmental expression of 
CNTF and its subcellular localization precluded a func-
tion of CNTF as a molecule regulating the survival of 
motoneurons during embryonic development, which 
takes place between E15 and PI in rats (74). However, 
the time period of natural motoneuron cell death is fol-
lowed by an augmented sensitivity to axonal damage. At 
birth, axotomy of motoneurons results in a virtually 
complete degeneration of the corresponding neuronal 
cell bodies (90, 93). This effect gradually decreases with 
increasing age. Since there is a striking reciprocity be-
tween the postnatal reduction in the sensitivity of moto-
neurons to axotomy and the developmental increase in 
CNTF expression in myelinating Schwann cells, we put 
forward the working hypothesis that CNTF might act as 
a "lesion factor ." Indeed, the local administration of 
CNTF after transection of the facial nerve in newborn 
rats virtually completely prevented the degeneration of 
the motoneuron cell bodies (93). Moreover, in adult ani-
mals, in spite of the reduction of the CNTF mRNA after 
transection of the sciatic nerve, the CNTF -assigned bio-
logical activity in the peripheral part of the sciatic nerve 
undergoing Wallerian degeneration was still about 1000 
times higher than the amount of " reactively" enhanced 
synthesis of NGF by non neuronal sciatic cells 1 week 
after lesion (35,97,98). Certainly, CNTF is not the sole 
factor responsible for motoneuron regeneration in pe-
ripheral nerves. The reactive synthesis of BDNF occur-
ring with a delay of about 7 days after axotomy (63) also 
shows features which are compatible with a supportive 
role of BDNF for the re growth ofaxons to the periph-
ery, taking over from the "first aid" function of CNTF. 
Very recent experiments with pmn mutant mice have 
provided further strong evidence for the function of 
CNTF as a lesion factor. Pmn mice show a strictly pro-
grammed, progressive .degeneration of motoneurons 
starting at the hind legs, progressing to the forelegs, and 
finally also affecting the motor nuclei of the brain stem, 
including the facial motor nucleus (91, 95). The transec-
tion of the facial nerve in pmn mice 2 weeks after the 
first clinical signs of motoneuron degeneration (hind 
legs) did not result in an enhanced but a delayed progres-
sion of facial motoneuron degeneration. Interestingly, 
in pmn mice crossbred with CNTF null mutants, the 
facial nerve lesion no longer resulted in a delay of facial 
motoneuron degeneration (Sendtner, unpublished re-
sults). 
Given that CNTF is expressed only postnatally and 
that it is a cytosolic molecule (100, 101), the question 
arose as to whether CNTF functions only under patho-
physiological conditions where, after nerve lesion, it 
might be released from its cytosolic site of production, 
or whether CNTF also has a physiological function re-
sulting from the release of CNTF from the cytosol ei-
ther by repetitive microtrauma or by a non-ER-Golgi 
unconventional release mechanism involving only a 
very small proportion of the cytosolic CNTF. To ad-
dress this issue, we used gene-targeting techniques to 
produce transgenic mice in which the CNTF gene was 
disrupted (60). As expected, CNTF null mutants ob -
tained by gene targeting resulting in a complete absence 
of CNTF protein and corresponding biological activity 
did not show a reduction of the number of motoneurons 
during embryonic development (60). Also during the 
first postnatal weeks, there was no evidence for atrophic 
or degenerative changes in motoneurons. However, mor-
phometric analysis of spinal motoneurons demon-
strated a gradually increasing atrophy and degeneration 
of motoneurons accompanied by reactive gliosis, start-
ing at the eighth postnatal week. By 28 weeks, a 22% 
reduction of the number of motoneurons in the facial 
nucleus was detectable (60). Although the motor func-
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tion from plain inspection did not indicate clear-cut 
signs of motoneuron impairment, measurement of grip 
strength as a parameter for motor function revealed a 
small but statistically significant reduction in 28-week-
old CNTF null mutants (60) . The fact that the clinical 
manifestation of impaired function in degenerative mo-
toneuron diseases does not occur before 50% of the mo-
toneurons have degenerated (67) and the statistically 
significant (P < 0.05) reduction in grip strength not only 
reflects the number of neurons lost but also an impaired 
function of at least part of the atrophic motoneurons. It 
has not yet been established whether the atrophic de-
generative processes will further continue or whether 
the process will stabilize, possibly due to compensatory 
enhanced production of other neurotrophic molecules 
coming into play, such as the reactive increase in BDNF 
formation observed after lesion of the sciatic nerve (63) . 
Thus, the available information permits the conclusion 
that CNTF has a distinct, although not exclusive, main-
tenance function for motoneurons in the postnatal 
phase, whereby the question of the mechanism of re-
lease from the cytosolic compartment remains unre-
solved. 
The predicted three-dimensional structures of 
CNTF, LIF, interleukin-6, and oncostatin-M (7)-in 
spite of the absence of significant sequence homologies 
-show common structural features which are also re-
flected by common signal-transducing units in the 
corresponding receptors (for review, see 42, 103). 
CNTF, LIF, and interleukin-6 share a common signal-
transducing unit, gp130, which is complemented by spe-
cific binding units. The intracellular domain of the LIF 
binding unit shares sequence homology with gp130. In-
terestingly, in addition to its (low affinity) GPI-linked 
binding unit (17), CNTF needs not only gp130 but also 
the LIF low-affinity binding unit for signal transduction 
(5,42). Thus, LIF, interleukin-6, and oncostatin-M de-
serve a thorough evaluation as additional potential 
neurotrophic molecules for motoneurons. Indeed, in vi-
tro and in vivo effects of LIF on motoneurons have been 
observed (34, 39, 58). However, the physiological rele-
vance of these observations remains to be established, 
particularly in view of the fact that a first evaluation of 
LIF -/- mice did not show any changes in spinal moto-
neurons either at the morphological or functional lev-
els (84). 
NEUROTROPHIC EFFECTS OF THE MEMBERS OF 
THE FIBROBLAST GROWTH FACTOR 
(FGF) GENE FAMILY 
In the same culture system of embryonic (E6) chick 
motoneurons in which the potent effects of CNTF were 
established, basic FGF (bFGF) demonstrated the sec-
ond-best survival effect both with respect to the extent 
(50% survival) and the half-maximal concentration 
(280 pg/m!). The effects of CNTF and bFGF were 
largely additive, their combination resulting in a long-
term 100% survival of chick embryonic motoneurons in 
culture (3). bFGF is broadly expressed in many embry-
onic tissues (28). However, because bFGF is not re -
leased according to the ER-Golgi secretory pathway 
and the mechanism(s) of a potential unconventional re -
lease is not known, bFGF is not a promising candidate 
for the regulatioI;l of motoneuron survival during embry-
onic development. However, another member of the 
FGF gene family, FGF -5, seems to fulfill the prerequi-
sites for a target-derived trophic factor for motoneu-
rons. FGF -5 shows a potent survival effect on both chick 
and rat motoneurons (38, 39). It is expressed in rat skele-
tal muscle from E15 to adulthood. Using an antiserum 
raised against a peptide from the C-terminus of FGF -5, 
which was able to precipitate recombinant FGF -5, 40-
50% of the survival activity present in embryonic rat 
skeletal muscle extract could be immunoprecipitated. 
In adult rat skeletal muscle the FGF -5-assigned survival 
activity was strongly matrix-bound and could only be 
released by high salt and EDTA (38). The relative con -
tribution of FGF -5 to the survival effect of rat skeletal 
muscle extract should be judged with caution, as cul-
tured chick embryonic motoneurons were used as an 
assay, and these cultures do not respond to any of the 
neurotrophins tested so far (3) (see below). Conversely, 
it has also to be emphasized that the potency of FG F-5 
in rat embryonic motoneuron cultures is about 10 times 
higher than in the corresponding cultures of chick moto -
neurons (39). 
NEUROTROPHIC EFFECTS OF MEMBERS OF THE 
NGF GENE FAMILY 
In the initial in vitro investigations with chick moto-
neurons no survival effect of any available member of 
the NGF gene family, even at very high concentrations, 
could be detected (3, 10). However, when it became ap-
parent that the mRNAs of BDNF, NT-3, and NT-4 /5 
are expressed in rat skeletal muscle during embryonic 
development and also adulthood (9, 36, 55), that the 
signal-transducing units mediating the effects of 
BDNF, NT-3, and NT-4/5, namely trkB and trkC, are 
expressed by motoneurons (26, 34), and that the specific 
retrograde axonal transport of labelled BDNF and NT-
3 was demonstrated (18), a reevaluation of the negative 
results obtained in vitro with chick motoneurons was 
mandatory. Indeed, independently four laboratories 
demonstrated an in vivo effect of BDNF on motoneu-
rons (45, 78, 96, 107). The administration of recombi-
nant BDNF on the chick embryo chorioallantoic mem-
brane resulted in an increased survival of spinal moto-
neurons (78) and, in newborn rats, the loss of 
motoneurons following lesion (sciatic or facial nerve) 
could be prevented by the local administration of recom-
bin ant BDNF (45, 96, 107) . Moreover, in the facial 
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nerve lesion paradigm, a lso NT -3 was found to have a 
rescue effect which, however, was smaller than that of 
BDNF (96). Very recently, a neuron rescue effect has 
also been observed in lesioned facial motoneurons after 
the administration of NT-4 (39). These in vivo effects 
have been complemented by the observation of survival 
effects of BDNF, NT-3, and NT-4/5 in vitro in rat moto-
neurons (34, 39). Consistently, under all in vitro and in 
vivo experimental conditions, no survival or rescue ef-
fect of NGF could be demonstrated (3, 10,34,39,65,96, 
107), which is also in agreement with the absence of 
detectable expression of trkA (34, 56), the signal-trans-
ducing receptor unit of NGF. On the contrary, there is 
experimental evidence that NGF even enhances the de-
generation of motoneurons and interferes with the sur-
vival action of other members of the NGF gene family in 
vitro and in vivo (39, 65, 96). 
INSULIN-LIKE GROWTH FACTOR UGF-I) 
The survival promoting effect of IGF -I in chick moto-
neurons in culture is very modest and only detectable at 
high concentrations (15 % survival at 1 JLg/ml) (3). In 
more recent experiments with rat motoneurons, a 
marked neurotrophic action of IG F -I has been observed, 
the maximal survival amounting to 50% at the half-
maximal concentration of 500 pg/ml (39). Moreover, 
IGF -I also exhibits a marked rescue effect in the new-
born rat facial nerve lesion paradigm (39). 
The very drastic difference between the survival ef-
fects of IGF -1 in chick compared to rat motoneurons in 
culture was due , most likely, to the different culture 
conditions. The culture medium used for chick motoneu-
rons contains horse serum (3) which has been shown to 
contain substantial amounts of IGF-I-binding proteins 
(83) which neutralize the biological activity ofIGF -I. It 
has been established that IGF-I is expressed by embry-
onic and adult skeletal muscle (14, 105), that its levels 
increase after skeletal muscle denervation (14), and 
that IGF -I exhibits an essential sprouting activity on 
motoneurons in vivo (13) . The relative physiological 
role of IGF -I as a neurotrophic molecule during embry-
onic development, and possibly also as a maintenance 
factor in adulthood, requires a careful evaluation to-
gether with the role of the increasing number of IGF-
binding proteins (6) which, at least partially, are coregu-
lated with IGF-I (46) and might play an important role 
in restricting the area of action of IGF-I and limit sys-
temic actions such as hypoglycemia and general growth 
(see Lewis et al. (48a), this issue). 
DISCORDANT RESULTS ORIGINATING FROM 
SPECIES DIFFERENCES AND DIFFERING CULTURE 
CONDITIONS: DISCREPANCIES BETWEEN IN VIVO 
AND IN VITRO EFFECTS 
The rapidly increasing number of molecules which 
exhibit neurotrophic actions on motoneurons has also 
left us with a se ries of di scorda nt findings which , a t least 
for the in vitro observa tions , can be explained by diffe r -
ences in the culture conditions (e. g., serum vs serum -
free medium), the preparation and select ion of motoneu -
rons, the "time window" se lected for the preparation of 
motoneurons, and al so hy species differences (3, 10,23, 
24, 33, 34, 39, 68). Mo reover, there are substantia l di s-
crepancies between in vitro and in vivo effects for given 
molecules. The elucidation of the reasons for these dis-
cordant results is not only of importance for the eluci-
dation of the relative-if any-physiological impor-
tance of the different molecules for the regulation of the 
embryonic survival of motoneurons and their differen -
tiation and maintenance in adulthood, but also with re-
spect to the potential use of these molecules for the 
treatment of traumatic and /or degenerative disorders 
of motoneurons. As it is impossible to discuss all of the 
details of discordant, or apparently discordant, results, 
we confine the discussion to a few aspects which are of 
potential importance with respect to the use of these 
molecules for the treatment of neurodegenerative dis-
eases. 
In initial experiments, Henderson and co-workers, 
using a panning method for the isolation of chick moto-
neurons, could not detect a survival effect of either 
CNTF and bFGF (10, 33). The method used had the 
advantage that it provided a virtually 100% pure popula-
tion of chick motoneurons. However, the epitope recog-
nized by the monoclonal antibody used for the panning 
procedure is only expressed up to E4.5 and therefore 
restricted the time period available for the analysis. In 
contrast, Arakawa and co-workers (3) used, from the 
point of view of the purity, a less ideal procedure per-
mitting the selection of an 80% pure population of moto-
neurons at E6, the beginning of the physiological death 
period of chick embryo motoneurons. After this isola-
tion and selection procedure, a very marked, potent sur-
vival effect ofCNTF became apparent (3 ). This discrep -
ancy could be explained by the preparation of the neu -
rons, e.g., the protease concentrations used damaging 
the CNTF receptor, but leaving intact the SCI-epitope 
used for the panning procedure. Alternatively, at E4.5, 
the CNTF signal-transducing multiunit receptor com-
plex might not yet be expressed in contrast to E6. A 
similar argumentation could be used for the complete 
lack of effect of all members of the neurotrophin gene 
family analyzed in E6 chick embryo motoneuron cul-
tures (3). Again, it could well be that the isolation proce-
dure used could have damaged the corresponding trk 
receptors but not the CNTF receptor complex or, at 
E-6, the relevant functional trk receptors are not yet 
present on motoneurons. Indeed, after an initial mainte-
nance period with CNTF a switch to BDNF or NT-3 
revealed a distinct survival effect of these two members 
of the NGF gene family (Hughes, unpublished results) . 
In contrast to chick motoneurons, E-15 rat embryonic 
TROPHIC SU PPORT OF MOTONEU RONS 51 
motoneurons showed a very marked response to BDNF, 
NT-3, and NT-4/5 (34,39). Conversely, the survival ef-
fect of CNTF in these rat motoneurons was distinctly 
below the effects observed in chick motoneurons (3, 34, 
39). The argumentations for the discrepancies are the 
same as those brought forward for the lacking effect of 
the members of the NGF gene family in chick moto-
neurons. 
Of particular interest is the complete discrepancy be-
tween the effects of FGFs (both bFGF and FGF-5) in 
vitro and in vivo (3, 38, 39, 70, 76) . For example, in con-
trast to the strong survival effects in vitro (both in chick 
and rat motoneuron cultures), both molecules were 
without protective effect against motoneuron degenera-
tion after lesioning of the newborn rat facial nerve (39). 
The amounts of locally administered bFGF and FGF-5 
corresponded to those of CNTF, BDNF, NT-3, NT-4, 
IGF-I, and LIF which showed a clear-cut, although dif-
fering, rescue effect (39, 45, 93, 94). The limited 
amounts of available recombinant FGF -5 did not permit 
experiments with excessively high quantities of re comb i-
nant FGF -5 as, for example, used for the demonstration 
of the protective effect of BDNF in the lesioned new-
born rat sciatic nerve (107). Also in chick embryos ad-
ministered to the chorioallantoic membrane, bFGF had 
no neurotrophic action on motoneurons (70, 76), al-
though it had a distinct mitogenic effect on other cell 
populations, excluding the possibility that bFGF was 
trapped by heparin-like molecules and prevented from 
reaching the site of action, i.e., motoneurons. However, 
very recently, Nurcombe and co-workers (71) demon-
strated that when aFGF was administered to the 
chorioallantoic membrane of chick embryos as a com-
plex with a specific heparan sulfate proteoglycan (72), a 
distinct neurotrophic effect on motoneurons could be 
observed (71). This would indicate that the essential 
complementary proteoglycan necessary for the signal 
transduction via the corresponding FGF receptor is 
present on cultivated FGF-responsive neurons, whereas 
it is not expressed in vivo. Tissue-specific expression of 
such proteoglycans might be responsible for the positive 
survival effects of bFGF on lesioned hypoglossal moto-
neurons in vivo (29), which are in disagreement with the 
negative effects observed by other investigations after 
in vivo administration of bFGF onto the chorioallantoic 
membrane of the chick embryo (70, 76). 
The elucidation of the discrepancies between in vitro 
and in vivo effects is essential not only with respect to 
understanding the importance of individual neurotro-
phic molecules for the trophic support of motoneurons 
during different developmental stages, but also to the 
crucial importance for the decision as to whether these 
molecules should be considered for therapeutic use in 
humans. Current and future experiments designed to 
elucidate the physiological function ofthe different mol-
ecules include the abolition of their expression by gene 
targeting, as described above for CNTF, by tissue (neu -
ron or muscle)-specific overexpression in transgenic 
animals, and by the reduction of expression using anti-
sense mRNA procedures and the systemic and/or local 
administration of blocking antibodies. Of particular in -
terest in the framework of the use of antibodies is the 
transgenic expression of specific antibodies under the 
control of a tissue-specific promoter (81), particularly 
when combined with a regulatory sequence which per-
mits the turning on or off of the antibody production . 
CRITERIA FOR SELECTING NEUROTROPHIC 
MOLECULES FOR CLINICAL TRIALS 
Because the use of neurotrophic molecules for the 
treatment of degenerative diseases of motoneurons rep -
resents a symptomatic rather than causal therapy, it is 
essential to collect information on the variety of models 
which could be of relevance for the human degenerative 
disorders. These include protection of motoneurons 
against lesion effects and protective effects on the pro-
gression of degenerative changes in animal mutants 
such as the pmn mouse (91), which exhibits characteris-
tics similar to ALS (15) , the mnd mouse (61,62), and the 
wobbler mutant (22, 43, 82), in which the paretic mani-
festations become apparent predominantly in the fore-
legs and do not reach levels as extreme as those in the 
case of the pmn mutant (91). Very recently, transgenic 
mice with a neuron-specific overexpression of light and 
heavy neurofilament chains have been created (16, 106) 
which show morphological changes of myelinating 
axons with similarities to the pathological picture of 
ALS patients (15). The impaired motoneuron function 
seems to result from an impairment of axonal transport 
(16,106) . The evaluation of the neurotrophic molecules 
considered for clinical trials in all these animal models 
will be of interest, and the observations made there will 
be of particular importance for future investigations as 
soon as the first clinical results, which are underway for 
CNTF (Lindsay et al. (50a), this issue) and IGF-I (Lewis 
et al. (48a) this issue), can be compared with the effects 
of these molecules in animal models. 
CRITERIA FOR THE EVALUATION OF 
NEUROTROPHIC MOLECULES IN ANIMAL MODELS 
AND CLINICAL TRIALS 
In vitro and in vivo experiments have demonstrated 
that, in order to exhibit their protective effect, neuro-
trophic factors have to be present continuously. There-
fore, in order to evaluate the effects of neurotrophic mol-
ecules, both in animal models and in clinical trials, it is 
essential, at least for the initial evaluation of whether 
the neurotrophic factor has the desired effect, that a 
constant level of the neurotrophic molecule at the site of 
action is accomplished. Although the technical invest-
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ments to reach this goal are distinctly higher than those 
for the administration of neurotrophic molecules by 
bolus injection, it has to be remembered that, for exam-
ple, the half-time of CNTF if injected intravenously is 4 
min (19). In this case, the main clearing site is the liver 
which is also the site of the most essential unwanted 
side effects, i.e., induction of acute phase proteins like 
haptoglobin and fibrinogen (5, 19, 92, 98) . In many 
cases, the effects of neurotrophic molecules on motoneu-
ron survival are additive (3, 39) and since the potential 
side effects of the different molecules, particularly of 
different gene families, are different, a combination of 
different neurotrophic molecules for the treatment of 
degenerative diseases should be envisaged under the 
aspect that, by their combination, a better ratio between 
the neurotrophic support and (unwanted) side effects 
could possibly be obtained. 
FUTURE PERSPECTIVES FOR THE TREATMENT OF 
DEGENERATIVE DISORDERS OF MOTONEURONS 
A more detailed understanding of the signal-trans-
duction mechanism(s) evolving from the interaction of 
neurotrophic molecules with their receptors and a bet-
ter understanding of the reasons why neurotrophic fac-
tors exhibit a general neuroprotective action against a 
variety of mechanical and chemical damages to neurons 
would open up new possibilities for a more focussed 
pharmacological modification of the cascade of signal 
transduction. First steps in these directions have very 
recently been made by synthesizing low molecular com-
pounds which modify, in a more or less specific manner, 
the tyrosine kinase activity of the trk receptor family 
(44) (see also Hempstead (32a), this issue). Conversely, 
an understanding of the molecular mechanisms respon-
sible for the pathological changes in human motoneu-
ron diseases (2,8,47,88) would permit a more selective 
choice of animal models for preclinical investigations. 
For the time being, one is left with a simple empirical 
approach, comparing the effects in animal models with 
the results of clinical investigations from case to case 
for individual neurotrophic molecules. Moreover, an 
understanding of the molecular mechanisms responsi-
ble for the degenerative disorders would also possibly 
open up new, more direct therapeutic approaches which 
interfere directly with the pathogenetic mechanism. 
The first promising indications in this direction have 
evolved from very recent reports indicating that, in a 
fraction of familial ALS cases (which represent about 
5% of all ALS patients), there are mutations in the su-
peroxide dismutase gene (87). However, it is not yet 
clear whether these mutations lead to an enhanced or 
reduced activity of the enzyme (87). Both an augmenta-
tion of the superoxide radical, in the case of reduced 
activity of superoxide dismutase, and the enhanced for-
mation of H 20 2 , in the case of augmented enzyme activ-
ity, could result in neuronal damage (reviewed in 47 
and 64). 
The fact that there are distinct discrepancies between 
the in vitro and in vivo effects of neurotrophic mole-
cules, particularly the lack of effect of all members of 
the FGF gene family in vivo (39, 70, 76) compared to 
their efficacy in vitro (3, 38, 39), raises the question of 
whether these molecules would need to be administered 
as a complex with an appropriate heparan sulfate glyco-
protein (71, 72) or whether better effects could be ob-
tained by the direct local administration, e.g., by direct 
gene transfer into the muscle (85), by engineering of 
(autologous) myoblasts in culture and their reimplanta-
tion, or by the use of viral systems (see 66). The ap-
proaches delineated here for the gene transfer into skel-
etal muscle could also be used for the local administra-
tion in peripheral nerves, such as the use of engineered 
autologous Schwann cells, and also in the spinal cord, as 
an alternative to the intrathecal infusion of neurotro-
phic molecules. This approach could be very useful for 
situations in which factors are unable to exert the de-
sired effects on motoneurons from the periphery, either 
because the corresponding receptors on nerve terminals 
or axons are damaged or because the signal-transduc-
tion mechanisms including retrograde transport are 
also impaired by the pathological disturbance. 
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